Genetics of the Acute Response to Oral Semaglutide (GAROS)
Study Details
Study Description
Brief Summary
The study aims to investigate the genetic basis of the response to short-term (3 months) orally administered semaglutide treatment, in terms of improving metabolic parameters, including the hormonal response to a standardized meal, and changes in body composition and liver steatosis. In the study, parameters such as fasting and 2-hour glucose during OGTT, HbA1c, body fat mass, body weight, total cholesterol, HDL and LDL, triglycerides, HOMA-IR, Matsuda Index and liver steatosis will be assessed. All the patients will undergo genome-wide genotyping. Moreover, in a subset of participants, muscle and fat biopsies will be performed, before and after the treatment, and liver, muscle and pancreas fat content will be assessed using MRI.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Each subject will participate in the following visits:
Visit v1 (screening) - for each patient, fasting venous blood will be collected and an oral glucose tolerance test (OGTT) will be performed - with blood samples taken 30, 60, 90 and 120 minutes after drinking the glucose solution. Fasting blood samples will be used to measure basic metabolic parameters (including glucose, lipid profile, HbA1c, AST, ALT, GGTP, electrolytes, blood count, the presence of antibodies against beta-cell antigens, TSH), and from blood collected at each time point during the OGTT glucose and insulin concentrations will be measured. Each patient will also undergo a detailed body composition analysis using bioimpedance and DXA. In addition, during the visit, each participant will receive a continuous glucose monitoring system (CGM) and an accelerometer to measure physical activity for a period of 10-14 days.
Visit v2 (1-3 days after v1)- during the visit, each patient will undergo a mixed meal tolerance test (MMTT) along with a non-invasive measurement of resting energy expenditure (RMR). After the end of the test, the patient will receive semaglutide in two marked doses: 3 mg and 7 mg, along with instructions on how to take them and a diary in which the drug intake and occurrence of side effects will be recorded. During the visit, an elastography examination of the liver will also be performed for the non-invasive assessment of fatty liver and fibrosis.
Visit v3 - four weeks after starting the semaglutide treatment. During the visit, fasting venous blood will be collected to measure basic metabolic parameters. Each patient will undergo a detailed body composition analysis using bioimpedance and DXA. During the visit, patients will receive semaglutide in the dose of 14 mg, along with instructions on how to take them and a diary in which the drug intake and occurrence of side effects will be recorded.
Visit v4 - after eight weeks of treatment with 14 mg of semaglutide. Similar to visit 1 (OGTT).
Visit v5 - after eight weeks of treatment with 14 mg of semaglutide. Similar to visit 2 (MMTT).
Additionally, a random 20% of the study group will participate in additional visits:
Visit A.1 (between visits v1 and v2) and A.2 (+ 1-5 days from visit v5) - during the visit, biological material will be collected for each patient in the form of a biopsy of the vastus lateralis muscle and subcutaneous adipose tissue.
Visit B.1 (between visits v1 and v2) and B.2 (+ 1-5 days from visit v5) - during the visit, patients will undergo an abdominal MRI scan to assess the steatosis of the liver, muscle and pancreas.
Visit v6 (follow-up visit) - after twelve weeks of ending the semaglutide treatment. Similar to visit 1 (OGTT).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Semaglutide (oral) In the project, each participant will receive oral semaglutide for three months. 3 mg a day for the first two weeks, then 7 mg a day for the next two weeks, until reaching a dose of 14 mg a day, which will be taken for the next eight weeks. |
Drug: Semaglutide Pill
Oral semaglutide treatment
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Glycemic measures - change in HbA1c (%) [1 and 3 months]
Investigators will measure the change in HbA1c concentration between Visit 2, Visit 3 and Visit 4 as an index of Semaglutide response, and compare them by genotype at selected loci.
- Body composition - change in body weight (kg) [1 and 3 months]
Investigators will measure the change in body weight measures between Visit 2, Visit 3 and Visit 4 as an index of Semaglutide response, and compare them by genotype at selected loci.
Secondary Outcome Measures
- Glycemic measures - change in 2-hour glucose (in mg/dl) [1 and 3 months]
Investigators will measure the change in 2-hour glucose measures (OGTT) between Visit 2, Visit 3 and Visit 4 as an index of Semaglutide response, and compare them by genotype at selected loci.
- Glycemic measures - change in fasting glucose (in mg/dl) [1 and 3 months]
Investigators will measure the change in fasting glucose measures between Visit 2, Visit 3 and Visit 4 as an index of Semaglutide response, and compare them by genotype at selected loci.
- Body composition - change in body fat content (kg) [1 and 3 months]
Investigators will measure the change in body fat content between Visit 2, Visit 3 and Visit 4 as an index of Semaglutide response, and compare them by genotype at selected loci.
- Body composition - change in lean body mass content (kg) [1 and 3 months]
Investigators will measure the change in lean body mass content between Visit 2, Visit 3 and Visit 4 as an index of Semaglutide response, and compare them by genotype at selected loci.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Informed consent was given before any study-related action on the subject.
-
Age: 18-65 years old
-
Body mass index (BMI) 30-43 kg/m2
-
Prediabetes, diagnosed according to the criteria of the American Diabetes Association
Exclusion Criteria:
-
Patients diagnosed with a serious chronic disease, including:
-
Ischemic heart disease
-
Heart failure (NYHA class III-IV)
-
Severe renal insufficiency (eGFR <30 ml/min)
-
Severe liver diseases
-
Inflammatory bowel disease
-
Diabetic gastroparesis
-
Cancer - currently or in the last five years prior to screening
-
Chronic obstructive pulmonary disease
-
History of mental illness, major depression or other severe mental disorders
-
Use of any medications with clinically-proven significant weight gain or loss effects
-
History of undergoing bariatric surgery or other surgery involving the stomach that could affect the absorption of the study drug (according to the investigator's opinion)
-
History of idiopathic acute pancreatitis
-
A family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid cancer
-
For women - pregnancy, breastfeeding or planning pregnancy.
-
Women of childbearing age who are not using highly effective methods of contraception
-
Known or suspected hypersensitivity to the test product
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Clinical Research Centre, Medical University of Bialystok | Bialystok | Podlaskie | Poland | 15-276 |
Sponsors and Collaborators
- Medical University of Bialystok
Investigators
- Principal Investigator: Lukasz Szczerbinski, MD, PhD, Clinical Research Centre, Medical University of Bialystok
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APK.002.12.2022